A survey from the American College of Rheumatology (ACR) revealed that patients with rheumatic diseases are struggling to get access to health care treatment.
A national survey of individuals with rheumatic diseases found that many face difficulties in obtaining access to care, with many forgoing physician care completely.
The survey was conducted in June by Rheumatic Disease Awareness Month 2020 and the American College of Rheumatology (ACR) and its Simple Tasks public awareness campaign. It builds on the ACR’s 2019 National Patient Survey and provides new insights into how issues regarding rheumatic diseases have changed over time and how the coronavirus disease 2019 (COVID-19) pandemic has impacted access to care.
“The survey findings show that Americans living with a rheumatic disease face significant challenges in their daily lives — including treatment access and affordability issues,” wrote the authors of the survey report.
The survey revealed that there has been a 52% decline in patients currently seeing a rheumatology provider between 2019 and 2020. In 2020, 33.5% of patients said they were currently receiving care, compared with 57.4% of respondents in 2019 who said they were being treated by a rheumatology provider. Of those in 2020 who reported that they were no longer being treated by a rheumatology provider, 38.23% said that they used to be.
Additionally, the survey found that reported wait times to be seen by a rheumatologist have increased since 2019, with 17.13% of patients reporting waiting between 61 to 90 days to get a first appointment with a rheumatologist following a referral, compared with 13.39% in 2019.
“These results could be attributed to factors such as the COVID-19 pandemic, an increase in the number of individuals without health insurance, and the growing nationwide shortage of rheumatology health professionals,” the authors wrote.
Almost half (49.20%) of respondents who receive a prescription medication for their rheumatic disease reported that medication shortages prevented them from being able to get their prescriptions filled. The most common out-of-stock medications included hydroxychloroquine, methotrexate, gabapentin, acetaminophen, and ibuprofen.
Prior authorization was required for nearly half (47.94%) of patients in 2020. Prior authorization requirements can restrict access to lower-cost medications such as biosimilars and prolong a patient’s waiting period before receiving treatment.
Affordability has also become an issue in 2020, with annual median out-of-pocket (OOP) expenses more than doubling over the past year. In 2019, the annual median OOP expense was $475 and rose to $1000 in 2020. Furthermore, in the June survey, 26.68% of patients reported spending more than $2000 in out-of-pocket costs.
About 66% of patients reported that they had taken advantage of telehealth within the past year, with 52% of patients citing the pandemic preventing them from being seen in the office as the main reason. Two other reasons cited for using telehealth were that the patient’s routine check0up didn’t require an in-office visit (49.52%) and that their rheumatologist was too far from where the patient lived (19.31%).
“It is critical for patients, clinicians, and policymakers to work together to improve rheumatology care so that those living with these diseases can live longer, healthier, and more fulfilling lives,” wrote the authors.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More